Stock data
Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc. (MDGL) reported revenue of US$958.40M and net income of -US$288.28M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$958.40M | — | -US$300.10M | -US$288.28M | — |
| 2024 | US$180.13M | — | -US$497.88M | -US$465.89M | — |
| 2023 | US$0.00M | — | -US$380.50M | -US$373.63M | — |
| 2022 | US$0.00M | — | -US$293.57M | -US$295.35M | — |
| 2021 | US$0.00M | — | -US$242.48M | -US$241.85M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$364.25M | -US$57.94M | — |
| 2026-03-31 | US$311.34M | -US$94.39M | — |
| 2025-12-31 | US$321.08M | -US$58.58M | — |
| 2025-09-30 | US$287.27M | -US$114.19M | — |
| 2025-06-30 | US$212.80M | -US$42.28M | — |
| 2025-03-31 | US$137.25M | -US$73.24M | — |
| 2024-12-31 | US$103.32M | -US$59.42M | — |
| 2024-09-30 | US$62.17M | -US$106.96M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.